Atara Biotherapeutics Registers Possible Resale of 400K Shares Atara filed to register 400,000 shares tied to an HCR warrant on Apr 3, 2026; the registration clarifies resale mechanics but does not itself issue shares.

Atara Biotherapeutics Registers Possible Resale of 400K Shares: Atara filed to register 400,000 shares tied to an HCR warrant on Apr 3, 2026; the registration clarifies resale mechanics but does not itself issue shares. 👈 Read full analysis #AtaraBiotherapeutics #Biotech #Pharma #Stocks #Investment

Atara Biotherapeutics Class Action Deadline Looms Investors in Atara Biotherapeutics (ATRA) urged to seek counsel after class action filed March 27, 2026; watch 21-day response windows and the 2/5 statute of limitations.

Atara Biotherapeutics Class Action Deadline Looms: Investors in Atara Biotherapeutics (ATRA) urged to seek counsel after class action filed March 27, 2026; watch 21-day response windows and the 2/5 statute of… 👈 Read full analysis #AtaraBiotherapeutics #ClassAction #Investors #ATRA #LegalCounsel

Atara Biotherapeutics’ Tab-cel® Receives FDA Priority Review for EBV+ Post-Transplant Lymphoproliferative Disease Atara Biotherapeutics (Nasdaq: ATRA) announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for tabelecleucel (tab-

Nasdaq: #ATRA
#Atarabiotherapeutics’ tab-cel has received FDA Priority Review for EBV+ PTLD, a rare post-transplant cancer. A decision is expected by Jan 15, 2025—potentially making it the first approved therapy for this life-threatening disease.
prismmarketview.com/atara-biothe...